SEC Form 4 · accession 0001140361-18-009201
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Feb 15, 2018
Accepted (ET)
Feb 20, 2018 · 8:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F3 | Feb 15, 2018 | M | 10,000 | $38.59 | A | 236,494 | D | |
| Common StockF1,F2,F3 | Feb 15, 2018 | S | 10,000 | $84.6285 | D | 226,494 | D | |
| Common StockF4 | holding | — | — | — | 182,201 | I | Shares held by Jean-Jacques Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F5 | $38.59 | Feb 15, 2018 | M | 10,000 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 10,000 | 172,500 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on November 14, 2017.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $84.095 to $84.98. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F3Amount of securities beneficially owned has been updated from the reporting person's prior report to include 600 shares reported in the Form 4 Amendment filed with the S.E.C. on 01/02/2018.
- F4Amount of securities beneficially owned has been updated from the reporting person's prior report to exclude 600 shares reported in the Form 4 Amendment filed with the S.E.C. on 01/02/2018.
- F5Reflects the number of stock options outstanding after the transaction from this specific stock option grant.